PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.


Journal

Cancer genetics
ISSN: 2210-7762
Titre abrégé: Cancer Genet
Pays: United States
ID NLM: 101539150

Informations de publication

Date de publication:
06 2022
Historique:
received: 19 10 2021
revised: 31 01 2022
accepted: 21 02 2022
pubmed: 10 3 2022
medline: 26 5 2022
entrez: 9 3 2022
Statut: ppublish

Résumé

The similarities between sporadic basal-like breast cancer (BLBC) and BRCA1-mutated breast tumours raise the possibility that deregulation of the same pathway may underlie these tumour types. The aim of this study was to determine if PTEN aberrations are characteristic of both BRCA1 tumours and sporadic TN breast carcinomas with low BRCA1 expression, and can thus be used to identify sporadic tumours potentially sensitive to PARP inhibitors. Twelve BRCA1 tumours, 19 non-BRCA familial breast tumours and 71 unselected TN breast carcinomas were screened for PTEN mutations and assessed for PTEN expression and BRCA1 mRNA expression. Loss of PTEN expression was observed in 67% of BRCA1 tumours and more specifically in 89% of TN BRCA1 tumours highlighting the link between PTEN loss and BLBC in the context of germline BRCA1 mutations. Regarding unselected TN tumours, 56% showed PTEN expression loss and 35% displayed low BRCA1 mRNA expression. Unlike familial breast cancers with low BRCA1 mRNA expression, no significant correlation was observed between the loss of PTEN expression and low BRCA1 mRNA expression in this unselected TN tumours panel. Our data suggest that, unlike the germinal context, PTEN and BRCA1 alterations in sporadic TN breast tumours are independent events.

Identifiants

pubmed: 35263698
pii: S2210-7762(22)00014-X
doi: 10.1016/j.cancergen.2022.02.008
pii:
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
RNA, Messenger 0
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-15

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Natalie Jones (N)

INSERM U1218, University of Bordeaux, Institut Bergonié, Bordeaux, France; Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Audrey Gros (A)

INSERM U1218, University of Bordeaux, Institut Bergonié, Bordeaux, France; Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Valérie Velasco (V)

Pathology Department, Institut Bergonié, Bordeaux, France.

Valérie Dapremont (V)

Biological Resource Centre, Institut Bergonié, Bordeaux, France.

Véronique Brouste (V)

Clinical & Epidemiological Research Unit, Institut Bergonié, Bordeaux, France.

Bernadette Gastaldello (B)

Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Marc Debled (M)

Medical Oncology Department, Institut Bergonié, Bordeaux, France.

Christine Tunon de Lara (C)

Department of Surgery, Institut Bergonié, Bordeaux, France.

Françoise Bonnet (F)

INSERM U1218, University of Bordeaux, Institut Bergonié, Bordeaux, France; Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Emmanuelle Barouk-Simonet (E)

Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Virginie Bubien (V)

Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Laurence Venat (L)

Medical Oncology Department, Dupuytren University Hospital, Limoges, France.

Gaëtan MacGrogan (G)

INSERM U1218, University of Bordeaux, Institut Bergonié, Bordeaux, France; Pathology Department, Institut Bergonié, Bordeaux, France.

Michel Longy (M)

INSERM U1218, University of Bordeaux, Institut Bergonié, Bordeaux, France; Cancer Genetics Unit, Institut Bergonié, Bordeaux, France.

Nicolas Sevenet (N)

INSERM U1218, University of Bordeaux, Institut Bergonié, Bordeaux, France; Cancer Genetics Unit, Institut Bergonié, Bordeaux, France; Faculty of Pharmacy, Univ. Bordeaux, Bordeaux, France. Electronic address: n.sevenet@bordeaux.unicancer.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH